Ying Liu

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen et al. · The Lancet Oncology · 2020 · 568 citations

Esophageal Cancer, Gastrointestinal Oncology, Medicine +10

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Kuimin Mei, Shukui Qin, Zhendong Chen et al. · Journal for ImmunoTherapy of Cancer · 2021 · 69 citations · Full text

Comparison of Current Diagnostic Criteria for Acute-On-Chronic Liver Failure

Qian Zhang, Ying Li, Tao Han et al. · PLoS ONE · 2015 · 60 citations · Full text

Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury

Wenjun Zhang, Simon J. Conway, Ying Liu et al. · Cells · 2021 · 53 citations · Full text

Osteopontin promotes collagen I synthesis in hepatic stellate cells by miRNA-129-5p inhibition

Yinghua Chen, Yitao Ou, Jiale Dong et al. · Experimental Cell Research · 2017 · 49 citations

Fibrosis, Developmental Biology, Hepatic Stellate Cells +6